NEW YORK (GenomeWeb News) – Transgenomic has asked the Nasdaq exchange to transfer its stock from the Global Market to the Capital Market in a bid to win time and regain compliance, according to documents filed with the Securities and Exchange Commission yesterday.
 
Transgenomic’s common stock does not meet Nasdaq's minimum $1 per share bid price to remain listed on the Global Market, the filing said.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers suggest that genetic variations could influence the side effects people experience when using synthetic cannabinoids, the International Business Times reports.

An analysis has examined the makeup of researchers on Twitter and what they share, Nature News reports.

At Stat News, Jim Kozubek argues that the Broad Institute is pushing the boundary of what a nonprofit is.

In PNAS this week: gut microbes may affect honeybee weight, phenotype and gene expression changes in DiGeorge syndrome, and more.